CYP2C19-guided antiplatelet therapyantiplatelet therapycardiovascular diseaseclopidogrelaspirinUIA
…th no statistically significant difference (P=0.388).Conclusion CYP2C19-guided antiplatelet therapy significantly reduces the risk of intracranial ischemic events …